Omnyx concludes UPMC affiliation, shutters headquarters

Omnyx, a digital pathology venture between UPMC and GE Healthcare, will cease its eight-year partnership with Pittsburgh-based UPMC when Omnyx is acquired by GE Healthcare at the end of December, Pittsburgh Post-Gazette reports.

Advertisement

Omnyx CFO Andy Chomos said regulatory uncertainty represented a “strong contributor” to leave independent operations and close the company’s Homestead, Penn., headquarters. GE Healthcare said in statement to Pittsburgh Post-Gazette the decision reflects a “variable global demand” for Omnyx’s technology, which allows physicians to examine digital tissue images.

Mr. Chomos said Omnyx has 85 employees, and the closing of its headquarters will result in “substantial downsizing,” though the number of affected employees was not specified.  

UPMC and GE Healthcare formed Omnyx in 2008, with each company owning 50 percent of the organization. UPMC and GE Healthcare agreed to contribute a combined $40 million to Omnyx. While Omnyx was estimated to control 25 percent of a projected $2 billion market for its pathology technology, the market did not develop as quickly as anticipated, according to the report.   

More articles on transactions and valuations:
CHS moves forward with sale of home health business
Northwestern University, AbbVie partner on oncology research
10 things you need to know about healthcare bankruptcies in 2017

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Reconsider What’s Possible: Enterprise RCM and the Pro-Fee Practice

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Garett Kreitz, Med-MetrixJohn Stefanowicz, Med-Metrix

Advertisement

Next Up in Transactions & Valuation Issues

Advertisement

Comments are closed.